JP2024524552A5 - - Google Patents
Info
- Publication number
- JP2024524552A5 JP2024524552A5 JP2024500258A JP2024500258A JP2024524552A5 JP 2024524552 A5 JP2024524552 A5 JP 2024524552A5 JP 2024500258 A JP2024500258 A JP 2024500258A JP 2024500258 A JP2024500258 A JP 2024500258A JP 2024524552 A5 JP2024524552 A5 JP 2024524552A5
- Authority
- JP
- Japan
- Prior art keywords
- refractory
- patient
- multiple myeloma
- received
- stem cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2109894.2 | 2021-07-08 | ||
| GBGB2109894.2A GB202109894D0 (en) | 2021-07-08 | 2021-07-08 | Novel treatments |
| GB2112976.2 | 2021-09-10 | ||
| GBGB2112976.2A GB202112976D0 (en) | 2021-09-10 | 2021-09-10 | Novel treatments |
| PCT/EP2022/068974 WO2023281007A1 (en) | 2021-07-08 | 2022-07-07 | Melflufen for use in the treatment of multiple myeloma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024524552A JP2024524552A (ja) | 2024-07-05 |
| JP2024524552A5 true JP2024524552A5 (cg-RX-API-DMAC7.html) | 2025-07-10 |
Family
ID=82702963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500258A Pending JP2024524552A (ja) | 2021-07-08 | 2022-07-07 | 多発性骨髄腫の治療に使用するためのメルフルフェン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240307480A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4366721A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024524552A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202317084A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023281007A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024121349A1 (en) * | 2022-12-08 | 2024-06-13 | Oncopeptides Ab | Therapeutic treatment for haematological cancer based on the level of t-cell function |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0002202D0 (sv) | 2000-06-13 | 2000-06-13 | Karolinska Innovations Ab | New peptides |
| SI3228319T1 (sl) | 2011-04-28 | 2020-10-30 | Oncopeptides Ab | Liofiliziran pripravek citotoksičnih dipeptidov |
| JP6284945B2 (ja) | 2012-10-26 | 2018-02-28 | オンコペプティデス エービーOncopeptides AB | メルファランフルフェナミドの凍結乾燥製剤 |
| GB201521217D0 (en) * | 2015-12-01 | 2016-01-13 | Oncopeptides Ab | Dosage regimens |
| WO2020079165A1 (en) | 2018-10-18 | 2020-04-23 | Oncopeptides Ab | Compounds containing deuterium |
| GB201905477D0 (en) | 2019-04-17 | 2019-05-29 | Oncopeptides Ab | Novel formulations |
-
2022
- 2022-07-07 US US18/576,878 patent/US20240307480A1/en active Pending
- 2022-07-07 EP EP22747660.3A patent/EP4366721A1/en active Pending
- 2022-07-07 WO PCT/EP2022/068974 patent/WO2023281007A1/en not_active Ceased
- 2022-07-07 JP JP2024500258A patent/JP2024524552A/ja active Pending
- 2022-07-08 TW TW111125748A patent/TW202317084A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020172502A5 (cg-RX-API-DMAC7.html) | ||
| US11826317B2 (en) | Combination therapy with notch and PD-1 or PD-L1 inhibitors | |
| RU2708246C2 (ru) | Комбинации лекарственных средств | |
| JP2022538237A5 (cg-RX-API-DMAC7.html) | ||
| JP2017525713A5 (cg-RX-API-DMAC7.html) | ||
| CA3142960A1 (en) | A formulation of a conjugate of a tubulysin analog to a cell-binding molecule | |
| CN103228142A (zh) | 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合 | |
| Mateos et al. | Novel generation of agents with proven clinical activity in multiple myeloma | |
| CN111265531A (zh) | 治疗和预防移植物抗宿主病的方法 | |
| US11241448B2 (en) | Methods for cancer therapy | |
| Nifosì et al. | Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology | |
| EP3860612A1 (en) | Immunoablative therapies | |
| CA2984464A1 (en) | Treatment for multiple myeloma (mm) | |
| JP2022508513A (ja) | がん治療のための併用療法 | |
| KR20240142500A (ko) | Psma-표적화 방사성제약 및 체크포인트 억제제 조합 요법 | |
| TW202131946A (zh) | 持續性免疫療法 | |
| JP6617220B2 (ja) | 免疫チェックポイント阻害剤による抗腫瘍効果を増強するための医薬組成物 | |
| JP2025503213A (ja) | Ntsr1標的化放射性医薬品およびチェックポイント阻害剤併用療法 | |
| US20100184732A1 (en) | Method of long-term treatment of graft-versus-host disease using topical active corticosteroids | |
| JP2024514163A5 (cg-RX-API-DMAC7.html) | ||
| Alia | biological treatment options of multiple myeloma | |
| TW202120092A (zh) | 化合物用於預防或治療移植物抗宿主病的用途 | |
| WO2022016231A1 (en) | Methods of treatment | |
| HK40124218A (en) | Composition and method for prolong survival of transplant and recipient | |
| Lonial et al. | Oral Selinexor Shows Single Agent Activity Enhanced With PI or IMID Combinations in Refractory Multiple Myeloma (MM) |